Truncated activin type II receptors inhibit bioactivity by the formation of heteromeric complexes with activin type I. receptors. Exp. Cell Res. May 1996
Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI. ErbB receptors: from oncogenes to targeted cancer therapies. J. Clin. Invest. August